PUBLISHER: Fortune Business Insights Pvt. Ltd. | PRODUCT CODE: 1916496
PUBLISHER: Fortune Business Insights Pvt. Ltd. | PRODUCT CODE: 1916496
Prostate Cancer Therapeutics Market Size, Share, Growth and Global Industry Analysis By Type & Application, Regional Insights and Forecast to 2026-2034
Growth Factors of prostate cancer therapeutics Market
The global prostate cancer therapeutics market represents one of the fastest-growing segments within the oncology landscape, driven by the rising incidence of prostate cancer among aging male populations and the rapid advancement of targeted and precision therapies. In 2025, the global prostate cancer therapeutics market was valued at USD 25.12 billion. With increasing diagnosis rates and wider adoption of advanced treatment modalities, the market is projected to grow to USD 34.35 billion in 2026 and further expand significantly to USD 106.86 billion by 2034, reflecting strong momentum throughout the forecast period.
Prostate cancer primarily affects older men, with a majority of diagnoses occurring in individuals aged 65 years and above. Rising awareness campaigns, routine prostate-specific antigen (PSA) screening, and improved access to healthcare services are contributing to higher diagnosis rates. As a result, demand for effective therapeutic options-ranging from hormone therapy to advanced targeted and immunotherapies-continues to accelerate globally.
Market Dynamics
A key driver supporting market expansion is the rising global prevalence of prostate cancer. According to global cancer databases, prostate cancer remains one of the most commonly diagnosed malignancies in men worldwide. Early diagnosis initiatives and awareness programs, such as annual global prostate cancer awareness campaigns, are further contributing to treatment adoption.
However, the market faces notable restraints. Resistance to hormone therapy, particularly the development of castration-resistant prostate cancer, reduces long-term treatment effectiveness. Additionally, adverse effects associated with chemotherapy and hormonal treatments-such as fatigue, bone density loss, and metabolic complications-can limit therapy continuation in some patients.
Despite these challenges, strong research and development investments are opening new growth avenues. Pharmaceutical companies are increasingly focusing on combination therapies, pairing androgen receptor inhibitors with PARP inhibitors, radioligand therapies, and androgen deprivation therapy to overcome resistance and improve outcomes in advanced disease stages.
Market Trends
One of the most prominent trends in the prostate cancer therapeutics market is the shift toward targeted and personalized medicine. Therapies designed for patients with specific genetic mutations, such as BRCA1 and BRCA2, are gaining traction. The increasing approval of radiopharmaceuticals and precision oncology drugs is reshaping treatment pathways, especially for metastatic castration-resistant prostate cancer.
Additionally, oral drug formulations are gaining preference due to better patient compliance and convenience in long-term disease management, contributing to their growing market share.
Segmentation Insights
By drug class, androgen receptor inhibitors account for the largest share of the market, supported by their effectiveness in blocking testosterone-driven cancer progression. In 2026, this segment is projected to hold over 70% of the total market share, reflecting its role as a first-line therapy in advanced cases.
By route of administration, oral therapies dominate due to ease of use and improved adherence, while parenteral therapies continue to play an important role in advanced and hospital-based treatment settings.
From a therapy perspective, hormonal therapy remains a cornerstone of prostate cancer management, followed by targeted therapy and immunotherapy. The metastatic castration-resistant prostate cancer segment represents the largest disease-state share, owing to its high treatment demand and increasing number of regulatory approvals.
Regional Outlook
North America dominated the global prostate cancer therapeutics market in 2025, accounting for 51.37% of total market share, supported by advanced healthcare infrastructure, high diagnosis rates, and rapid adoption of novel therapies. The regional market was valued at USD 12.9 billion in 2025 and increased to USD 18.08 billion in 2026.
Europe represents the second-largest regional market, driven by rising disease prevalence and strong regulatory support for innovative oncology drugs. Asia Pacific is emerging as a high-growth region, supported by increasing cancer incidence, expanding healthcare access, and strategic collaborations between global and regional pharmaceutical companies.
Competitive Landscape
The market is highly competitive, with leading pharmaceutical and biopharmaceutical companies actively investing in clinical trials, regulatory approvals, and strategic collaborations. Key players include Pfizer Inc., Johnson & Johnson Services, Inc., Astellas Pharma Inc., AstraZeneca, AbbVie Inc., and Bayer AG. Recent years have seen a surge in pipeline activity, particularly in radioligand therapies and next-generation targeted treatments, reinforcing long-term market expansion prospects.
Report Coverage
The prostate cancer therapeutics market report provides a comprehensive and in-depth analysis of the global industry landscape, focusing on market size, growth trajectory, and competitive dynamics in line with the report years 2025, 2026, and 2034. The study covers detailed insights across key parameters, including market drivers, restraints, opportunities, challenges, and emerging trends influencing the adoption of prostate cancer treatments worldwide.
The report evaluates the market across multiple segmentation categories such as drug class, route of administration, therapy type, disease state, and distribution channel, offering a granular understanding of demand patterns and treatment preferences. In addition, it presents a thorough regional assessment covering North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa, highlighting region-wise market size, growth potential, and regulatory environments.
Furthermore, the report includes an extensive competitive landscape analysis, profiling leading pharmaceutical and biopharmaceutical companies, their product portfolios, strategic initiatives, pipeline developments, and recent regulatory approvals. The impact of COVID-19, advances in targeted and personalized therapies, and the shift toward combination treatments are also analyzed to provide a holistic view of the market's evolution.
Conclusion
The global prostate cancer therapeutics market is positioned for robust and sustained growth, supported by the rising prevalence of prostate cancer, increasing diagnosis rates, and continuous advancements in oncology drug development. With a market valuation of USD 25.12 billion in 2025, the expansion to USD 34.35 billion in 2026 reflects accelerating adoption of advanced hormonal, targeted, and immunotherapies. The projected growth to USD 106.86 billion by 2034 underscores the long-term significance of innovation-driven treatment strategies in prostate cancer care.
While challenges such as therapy resistance, treatment-related side effects, and high costs remain, ongoing research into combination therapies, radiopharmaceuticals, and precision medicine is reshaping the treatment paradigm. North America continues to dominate due to strong healthcare infrastructure and rapid uptake of novel drugs, while Europe and Asia Pacific are emerging as key growth regions. Overall, aligned strictly with the report years 2025, 2026, and 2034, the prostate cancer therapeutics market is expected to remain a critical and rapidly evolving segment within the global oncology industry.
Segmentation By Drug Class
- Androgen Receptor Inhibitors
- Microtubule Inhibitors
- Gonadotropin Releasing Hormone (GnRH) Agonist
- Gonadotropin-Releasing Hormone (GnRH) Receptor Antagonist
- Others
By Route of Administration
- Oral
- Parenteral
By Therapy
- Chemotherapy
- Hormonal Therapy
- Targeted therapy
- Immunotherapy
By Disease State
- Metastatic Castration-Resistant Prostate Cancer
- Non-Metastatic Castration-Resistant Prostate Cancer
By Distribution Channel
- Hospital Pharmacies
- Drug Stores & Retail Pharmacies
- Online Pharmacies
By Region
- North America (By Drug Class, Route of Administration, Therapy Type, Disease State, Distribution Channel, and Country)
- U.S.
- Canada
- Europe (By Drug Class, Route of Administration, Therapy Type, Disease State, Distribution Channel, and Country/Sub-Region)
- U.K.
- Germany
- France
- Spain
- Italy
- Rest of Europe
- Asia Pacific (By Drug Class, Route of Administration, Therapy Type, Disease State, Distribution Channel, and Country/Sub-Region)
- Japan
- China
- India
- Australia
- Rest of Asia Pacific
- Latin America (By Drug Class, Route of Administration, Therapy Type, Disease State, Distribution Channel, and Country/Sub-Region)
- Brazil
- Mexico
- Rest of Latin America
- Middle East & Africa (By Drug Class, Route of Administration, Therapy Type, Disease State, Distribution Channel, and Country/Sub-Region)
- GCC
- South Africa
- Rest of the Middle East & Africa
Table of Content
1. Introduction
- 1.1. Research Scope
- 1.2. Market Segmentation
- 1.3. Research Methodology
- 1.4. Definitions and Assumptions
2. Executive Summary
3. Market Dynamics
- 3.1. Market Drivers
- 3.2. Market Restraints
- 3.3. Market Opportunities
- 3.4. Market Trends
4. Key Insights
- 4.1. Prevalence of Prostate Cancer - by Key Countries/Regions, 2025
- 4.2. Pipeline Analysis, by Key Players
- 4.3. Overview of Alternative Therapies
- 4.4. Key Start-ups in the Market
- 4.5. New Product Launches, by Key Players
- 4.6. Key Industry Developments (Mergers, Acquisitions, Partnerships, etc.)
- 4.7. Impact of COVID-19 on the Market
5. Global Prostate Cancer Therapeutics Market Analysis, Insights and Forecast, 2021-2034
- 5.1. Market Analysis, Insights and Forecast - By Drug Class
- 5.1.1. Androgen Receptor Inhibitors
- 5.1.2. Microtubule Inhibitors
- 5.1.3. Gonadotropin Releasing Hormone (GnRH) Agonist
- 5.1.4. Gonadotropin-Releasing Hormone (GnRH) Receptor Antagonist
- 5.1.5. Others
- 5.2. Market Analysis, Insights and Forecast - By Route of Administration
- 5.2.1. Oral
- 5.2.2. Parenteral
- 5.3. Market Analysis, Insights and Forecast - By Therapy
- 5.3.1. Chemotherapy
- 5.3.2. Hormonal Therapy
- 5.3.3. Targeted therapy
- 5.3.4. Immunotherapy
- 5.4. Market Analysis, Insights and Forecast - By Disease State
- 5.4.1. Metastatic Castration-Resistant Prostate Cancer
- 5.4.2. Non-Metastatic Castration-Resistant Prostate Cancer
- 5.5. Market Analysis, Insights and Forecast - By Distribution Channel
- 5.5.1. Hospital Pharmacies
- 5.5.2. Drug Stores & Retail Pharmacies
- 5.5.3. Online Pharmacies
- 5.6. Market Analysis, Insights and Forecast - Region
- 5.6.1. North America
- 5.6.2. Europe
- 5.6.3. Asia Pacific
- 5.6.4. Latin America
- 5.6.5. Middle East & Africa
6. North America Prostate Cancer Therapeutics Market Analysis, Insights and Forecast, 2021-2034
- 6.1. Market Analysis, Insights and Forecast - By Drug Class
- 6.1.1. Androgen Receptor Inhibitors
- 6.1.2. Microtubule Inhibitors
- 6.1.3. Gonadotropin Releasing Hormone (GnRH) Agonist
- 6.1.4. Gonadotropin-Releasing Hormone (GnRH) Receptor Antagonist
- 6.1.5. Others
- 6.2. Market Analysis, Insights and Forecast - By Route of Administration
- 6.2.1. Oral
- 6.2.2. Parenteral
- 6.3. Market Analysis, Insights and Forecast - By Therapy
- 6.3.1. Chemotherapy
- 6.3.2. Hormonal Therapy
- 6.3.3. Targeted therapy
- 6.3.4. Immunotherapy
- 6.4. Market Analysis, Insights and Forecast - By Disease State
- 6.4.1. Metastatic Castration-Resistant Prostate Cancer
- 6.4.2. Non-Metastatic Castration-Resistant Prostate Cancer
- 6.5. Market Analysis, Insights and Forecast - By Distribution Channel
- 6.5.1. Hospital Pharmacies
- 6.5.2. Drug Stores & Retail Pharmacies
- 6.5.3. Online Pharmacies
- 6.6. Market Analysis, Insights and Forecast - By Country
- 6.6.1. U.S.
- 6.6.2. Canada
7. Europe Prostate Cancer Therapeutics Market Analysis, Insights and Forecast, 2021-2034
- 7.1. Market Analysis, Insights and Forecast - By Drug Class
- 7.1.1. Androgen Receptor Inhibitors
- 7.1.2. Microtubule Inhibitors
- 7.1.3. Gonadotropin Releasing Hormone (GnRH) Agonist
- 7.1.4. Gonadotropin-Releasing Hormone (GnRH) Receptor Antagonist
- 7.1.5. Others
- 7.2. Market Analysis, Insights and Forecast - By Route of Administration
- 7.2.1. Oral
- 7.2.2. Parenteral
- 7.3. Market Analysis, Insights and Forecast - By Therapy
- 7.3.1. Chemotherapy
- 7.3.2. Hormonal Therapy
- 7.3.3. Targeted therapy
- 7.3.4. Immunotherapy
- 7.4. Market Analysis, Insights and Forecast - By Disease State
- 7.4.1. Metastatic Castration-Resistant Prostate Cancer
- 7.4.2. Non-Metastatic Castration-Resistant Prostate Cancer
- 7.5. Market Analysis, Insights and Forecast - By Distribution Channel
- 7.5.1. Hospital Pharmacies
- 7.5.2. Drug Stores & Retail Pharmacies
- 7.5.3. Online Pharmacies
- 7.6. Market Analysis, Insights and Forecast - By Country/ Sub-Region
- 7.6.1. Germany
- 7.6.2. U.K.
- 7.6.3. France
- 7.6.4. Italy
- 7.6.5. Spain
- 7.6.6. Scandinavia
- 7.6.7. Rest of Europe
8. Asia Pacific Prostate Cancer Therapeutics Market Analysis, Insights and Forecast, 2021-2034
- 8.1. Market Analysis, Insights and Forecast - By Drug Class
- 8.1.1. Androgen Receptor Inhibitors
- 8.1.2. Microtubule Inhibitors
- 8.1.3. Gonadotropin Releasing Hormone (GnRH) Agonist
- 8.1.4. Gonadotropin-Releasing Hormone (GnRH) Receptor Antagonist
- 8.1.5. Others
- 8.2. Market Analysis, Insights and Forecast - By Route of Administration
- 8.2.1. Oral
- 8.2.2. Parenteral
- 8.3. Market Analysis, Insights and Forecast - By Therapy
- 8.3.1. Chemotherapy
- 8.3.2. Hormonal Therapy
- 8.3.3. Targeted therapy
- 8.3.4. Immunotherapy
- 8.4. Market Analysis, Insights and Forecast - By Disease State
- 8.4.1. Metastatic Castration-Resistant Prostate Cancer
- 8.4.2. Non-Metastatic Castration-Resistant Prostate Cancer
- 8.5. Market Analysis, Insights and Forecast - By Distribution Channel
- 8.5.1. Hospital Pharmacies
- 8.5.2. Drug Stores & Retail Pharmacies
- 8.5.3. Online Pharmacies
- 8.6. Market Analysis, Insights and Forecast - By Country/ Sub-Region
- 8.6.1. China
- 8.6.2. Japan
- 8.6.3. India
- 8.6.4. Australia
- 8.6.5. Southeast Asia
- 8.6.6. Rest of Asia Pacific
9. Latin America Prostate Cancer Therapeutics Market Analysis, Insights and Forecast, 2021-2034
- 9.1. Market Analysis, Insights and Forecast - By Drug Class
- 9.1.1. Androgen Receptor Inhibitors
- 9.1.2. Microtubule Inhibitors
- 9.1.3. Gonadotropin Releasing Hormone (GnRH) Agonist
- 9.1.4. Gonadotropin-Releasing Hormone (GnRH) Receptor Antagonist
- 9.1.5. Others
- 9.2. Market Analysis, Insights and Forecast - By Route of Administration
- 9.2.1. Oral
- 9.2.2. Parenteral
- 9.3. Market Analysis, Insights and Forecast - By Therapy
- 9.3.1. Chemotherapy
- 9.3.2. Hormonal Therapy
- 9.3.3. Targeted therapy
- 9.3.4. Immunotherapy
- 9.4. Market Analysis, Insights and Forecast - By Disease State
- 9.4.1. Metastatic Castration-Resistant Prostate Cancer
- 9.4.2. Non-Metastatic Castration-Resistant Prostate Cancer
- 9.5. Market Analysis, Insights and Forecast - By Distribution Channel
- 9.5.1. Hospital Pharmacies
- 9.5.2. Drug Stores & Retail Pharmacies
- 9.5.3. Online Pharmacies
- 9.6. Market Analysis, Insights and Forecast - By Country/ Sub-Region
- 9.6.1. Brazil
- 9.6.2. Mexico
- 9.6.3. Rest of Latin America
10. Middle East & Africa Prostate Cancer Therapeutics Market Analysis, Insights and Forecast, 2021-2034
- 10.1. Market Analysis, Insights and Forecast - By Drug Class
- 10.1.1. Androgen Receptor Inhibitors
- 10.1.2. Microtubule Inhibitors
- 10.1.3. Gonadotropin Releasing Hormone (GnRH) Agonist
- 10.1.4. Gonadotropin-Releasing Hormone (GnRH) Receptor Antagonist
- 10.1.5. Others
- 10.2. Market Analysis, Insights and Forecast - By Route of Administration
- 10.2.1. Oral
- 10.2.2. Parenteral
- 10.3. Market Analysis, Insights and Forecast - By Therapy
- 10.3.1. Chemotherapy
- 10.3.2. Hormonal Therapy
- 10.3.3. Targeted therapy
- 10.3.4. Immunotherapy
- 10.4. Market Analysis, Insights and Forecast - By Disease State
- 10.4.1. Metastatic Castration-Resistant Prostate Cancer
- 10.4.2. Non-Metastatic Castration-Resistant Prostate Cancer
- 10.5. Market Analysis, Insights and Forecast - By Distribution Channel
- 10.5.1. Hospital Pharmacies
- 10.5.2. Drug Stores & Retail Pharmacies
- 10.5.3. Online Pharmacies
- 10.6. Market Analysis, Insights and Forecast - By Country/ Sub-Region
- 10.6.1. GCC
- 10.6.2. South Africa
- 10.6.3. Rest of Middle East & Africa
11. Competitive Analysis
- 11.1. Global Market Share Analysis (2025)
- 11.2. Company Profiles
- 11.2.1. Astellas Pharma Inc.
- 11.2.1.1. Overview
- 11.2.1.2. Products
- 11.2.1.3. SWOT Analysis
- 11.2.1.4. Recent Developments
- 11.2.1.5. Strategies
- 11.2.1.6. Financials (Based on Availability)
- 11.2.2. Pfizer Inc.
- 11.2.2.1. Overview
- 11.2.2.2. Products
- 11.2.2.3. SWOT Analysis
- 11.2.2.4. Recent Developments
- 11.2.2.5. Strategies
- 11.2.2.6. Financials (Based on Availability)
- 11.2.3. Johnson & Johnson Services, Inc.
- 11.2.3.1. Overview
- 11.2.3.2. Products
- 11.2.3.3. SWOT Analysis
- 11.2.3.4. Recent Developments
- 11.2.3.5. Strategies
- 11.2.3.6. Financials (Based on Availability)
- 11.2.4. Sanofi
- 11.2.4.1. Overview
- 11.2.4.2. Products
- 11.2.4.3. SWOT Analysis
- 11.2.4.4. Recent Developments
- 11.2.4.5. Strategies
- 11.2.4.6. Financials (Based on Availability)
- 11.2.5. Ferring Pharmaceuticals Inc.
- 11.2.5.1. Overview
- 11.2.5.2. Products
- 11.2.5.3. SWOT Analysis
- 11.2.5.4. Recent Developments
- 11.2.5.5. Strategies
- 11.2.5.6. Financials (Based on Availability)
- 11.2.6. Sumitomo Pharma Co., Ltd. (Myovant Sciences GmbH)
- 11.2.6.1. Overview
- 11.2.6.2. Products
- 11.2.6.3. SWOT Analysis
- 11.2.6.4. Recent Developments
- 11.2.6.5. Strategies
- 11.2.6.6. Financials (Based on Availability)
- 11.2.7. AbbVie Inc.
- 11.2.7.1. Overview
- 11.2.7.2. Products
- 11.2.7.3. SWOT Analysis
- 11.2.7.4. Recent Developments
- 11.2.7.5. Strategies
- 11.2.7.6. Financials (Based on Availability)
- 11.2.8. AstraZeneca
- 11.2.8.1. Overview
- 11.2.8.2. Products
- 11.2.8.3. SWOT Analysis
- 11.2.8.4. Recent Developments
- 11.2.8.5. Strategies
- 11.2.8.6. Financials (Based on Availability)
- 11.2.9. Tolmar, Inc.
- 11.2.9.1. Overview
- 11.2.9.2. Products
- 11.2.9.3. SWOT Analysis
- 11.2.9.4. Recent Developments
- 11.2.9.5. Strategies
- 11.2.9.6. Financials (Based on Availability)
- 11.2.10. Dendreon Pharmaceuticals LLC.
- 11.2.10.1. Overview
- 11.2.10.2. Products
- 11.2.10.3. SWOT Analysis
- 11.2.10.4. Recent Developments
- 11.2.10.5. Strategies
- 11.2.10.6. Financials (Based on Availability)
- 11.2.11. Bayer AG
- 11.2.11.1. Overview
- 11.2.11.2. Products
- 11.2.11.3. SWOT Analysis
- 11.2.11.4. Recent Developments
- 11.2.11.5. Strategies
- 11.2.11.6. Financials (Based on Availability)
- 11.2.1. Astellas Pharma Inc.
List of Tables
- Table 1: Global Prostate Cancer Therapeutics Market Revenue (USD billion) Forecast, by Drug Class, 2021-2034
- Table 2: Global Prostate Cancer Therapeutics Market Revenue (USD billion) Forecast, by Route of Administration, 2021-2034
- Table 3: Global Prostate Cancer Therapeutics Market Revenue (USD billion) Forecast, by Therapy 2021-2034
- Table 4: Global Prostate Cancer Therapeutics Market Revenue (USD billion) Forecast, by Disease State, 2021-2034
- Table 5: Global Prostate Cancer Therapeutics Market Revenue (USD billion) Forecast, by Distribution Channel, 2021-2034
- Table 6: Global Prostate Cancer Therapeutics Market Revenue (USD billion) Forecast, by Region, 2021-2034
- Table 7: North America Prostate Cancer Therapeutics Market Revenue (USD billion) Forecast, by Drug Class, 2021-2034
- Table 8: North America Prostate Cancer Therapeutics Market Revenue (USD billion) Forecast, by Route of Administration, 2021-2034
- Table 9: North America Prostate Cancer Therapeutics Market Revenue (USD billion) Forecast, by Therapy 2021-2034
- Table 10: North America Prostate Cancer Therapeutics Market Revenue (USD billion) Forecast, by Disease State, 2021-2034
- Table 11: North America Prostate Cancer Therapeutics Market Revenue (USD billion) Forecast, by Distribution Channel, 2021-2034
- Table 12: North America Prostate Cancer Therapeutics Market Revenue (USD billion) Forecast, By Country, 2021-2034
- Table 13: Europe Prostate Cancer Therapeutics Market Revenue (USD billion) Forecast, by Drug Class, 2021-2034
- Table 14: Europe Prostate Cancer Therapeutics Market Revenue (USD billion) Forecast, by Route of Administration, 2021-2034
- Table 15: Europe Prostate Cancer Therapeutics Market Revenue (USD billion) Forecast, by Therapy 2021-2034
- Table 16: Europe Prostate Cancer Therapeutics Market Revenue (USD billion) Forecast, by Disease State, 2021-2034
- Table 17: Europe Prostate Cancer Therapeutics Market Revenue (USD billion) Forecast, by Distribution Channel, 2021-2034
- Table 18: Europe Prostate Cancer Therapeutics Market Revenue (USD billion) Forecast, By Country/ Sub-region, 2021-2034
- Table 19: Asia Pacific Prostate Cancer Therapeutics Market Revenue (USD billion) Forecast, by Drug Class, 2021-2034
- Table 20: Asia Pacific Prostate Cancer Therapeutics Market Revenue (USD billion) Forecast, by Route of Administration, 2021-2034
- Table 21: Asia Pacific Prostate Cancer Therapeutics Market Revenue (USD billion) Forecast, by Therapy 2021-2034
- Table 22: Asia Pacific Prostate Cancer Therapeutics Market Revenue (USD billion) Forecast, by Disease State, 2021-2034
- Table 23: Asia Pacific Prostate Cancer Therapeutics Market Revenue (USD billion) Forecast, by Distribution Channel, 2021-2034
- Table 24: Asia Pacific Prostate Cancer Therapeutics Market Revenue (USD billion) Forecast, By Country/ Sub-region, 2021-2034
- Table 25: Latin America Prostate Cancer Therapeutics Market Revenue (USD billion) Forecast, by Drug Class, 2021-2034
- Table 26: Latin America Prostate Cancer Therapeutics Market Revenue (USD billion) Forecast, by Route of Administration, 2021-2034
- Table 27: Latin America Prostate Cancer Therapeutics Market Revenue (USD billion) Forecast, by Therapy 2021-2034
- Table 28: Latin America Prostate Cancer Therapeutics Market Revenue (USD billion) Forecast, by Disease State, 2021-2034
- Table 29: Latin America Prostate Cancer Therapeutics Market Revenue (USD billion) Forecast, by Distribution Channel, 2021-2034
- Table 30: Latin America Prostate Cancer Therapeutics Market Revenue (USD billion) Forecast, By Country/ Sub-region, 2021-2034
- Table 31: Middle East & Africa Prostate Cancer Therapeutics Market Revenue (USD billion) Forecast, by Drug Class, 2021-2034
- Table 32: Middle East & Africa Prostate Cancer Therapeutics Market Revenue (USD billion) Forecast, by Route of Administration, 2021-2034
- Table 33: Middle East & Africa Prostate Cancer Therapeutics Market Revenue (USD billion) Forecast, by Therapy 2021-2034
- Table 34: Middle East & Africa Prostate Cancer Therapeutics Market Revenue (USD billion) Forecast, by Disease State, 2021-2034
- Table 35: Middle East & Africa Prostate Cancer Therapeutics Market Revenue (USD billion) Forecast, by Distribution Channel, 2021-2034
- Table 36: Middle East & Africa Prostate Cancer Therapeutics Market Revenue (USD billion) Forecast, By Country/ Sub-region, 2021-2034
List of Figures
- Figure 1: Global Prostate Cancer Therapeutics Market Revenue Breakdown (USD billion, %) by Region, 2025 & 2034
- Figure 2: Global Prostate Cancer Therapeutics Market Value Share (%), by Drug Class, 2025 & 2034
- Figure 3: Global Prostate Cancer Therapeutics Market Value Share (%), by Route of Administration, 2025 & 2034
- Figure 4: Global Prostate Cancer Therapeutics Market Value Share (%), by Therapy, 2025 & 2034
- Figure 5: Global Prostate Cancer Therapeutics Market Value Share (%), by Disease State, 2025 & 2034
- Figure 6: Global Prostate Cancer Therapeutics Market Value Share (%), by Distribution Channel, 2025 & 2034
- Figure 7: Global Prostate Cancer Therapeutics Market Value (USD billion), by Region, 2025 & 2034
- Figure 8: North America Prostate Cancer Therapeutics Market Value (USD billion), by Drug Class, 2025 & 2034
- Figure 9: North America Prostate Cancer Therapeutics Market Value Share (%), by Drug Class, 2025
- Figure 10: North America Prostate Cancer Therapeutics Market Value (USD billion), by Route of Administration, 2025 & 2034
- Figure 11: North America Prostate Cancer Therapeutics Market Value Share (%), by Route of Administration, 2025
- Figure 12: North America Prostate Cancer Therapeutics Market Value (USD billion), by Therapy, 2025 & 2034
- Figure 13: North America Prostate Cancer Therapeutics Market Value Share (%), by Therapy, 2025
- Figure 14: North America Prostate Cancer Therapeutics Market Value (USD billion), by Disease State, 2025 & 2034
- Figure 15: North America Prostate Cancer Therapeutics Market Value Share (%), by Disease State, 2025
- Figure 16: North America Prostate Cancer Therapeutics Market Value (USD billion), by Distribution Channel, 2025 & 2034
- Figure 17: North America Prostate Cancer Therapeutics Market Value Share (%), by Distribution Channel, 2025
- Figure 18: North America Prostate Cancer Therapeutics Market Value (USD billion), By Country, 2025 & 2034
- Figure 19: North America Prostate Cancer Therapeutics Market Value Share (%), By Country, 2025
- Figure 20: Europe Prostate Cancer Therapeutics Market Value (USD billion), by Drug Class, 2025 & 2034
- Figure 21: Europe Prostate Cancer Therapeutics Market Value Share (%), by Drug Class, 2025
- Figure 22: Europe Prostate Cancer Therapeutics Market Value (USD billion), by Route of Administration, 2025 & 2034
- Figure 23: Europe Prostate Cancer Therapeutics Market Value Share (%), by Route of Administration, 2025
- Figure 24: Europe Prostate Cancer Therapeutics Market Value (USD billion), by Therapy, 2025 & 2034
- Figure 25: Europe Prostate Cancer Therapeutics Market Value Share (%), by Therapy, 2025
- Figure 26: Europe Prostate Cancer Therapeutics Market Value (USD billion), by Disease State, 2025 & 2034
- Figure 27: Europe Prostate Cancer Therapeutics Market Value Share (%), by Disease State, 2025
- Figure 28: Europe Prostate Cancer Therapeutics Market Value (USD billion), by Distribution Channel, 2025 & 2034
- Figure 29: Europe Prostate Cancer Therapeutics Market Value Share (%), by Distribution Channel, 2025
- Figure 30: Europe Prostate Cancer Therapeutics Market Value (USD billion), By Country/ Sub-region, 2025 & 2034
- Figure 31: Europe Prostate Cancer Therapeutics Market Value Share (%), By Country/ Sub-region, 2025
- Figure 32: Asia Pacific Prostate Cancer Therapeutics Market Value (USD billion), by Drug Class, 2025 & 2034
- Figure 33: Asia Pacific Prostate Cancer Therapeutics Market Value Share (%), by Drug Class, 2025
- Figure 34: Asia Pacific Prostate Cancer Therapeutics Market Value (USD billion), by Route of Administration, 2025 & 2034
- Figure 35: Asia Pacific Prostate Cancer Therapeutics Market Value Share (%), by Route of Administration, 2025
- Figure 36: Asia Pacific Prostate Cancer Therapeutics Market Value (USD billion),by Therapy, 2025 & 2034
- Figure 37: Asia Pacific Prostate Cancer Therapeutics Market Value Share (%), by Therapy, 2025
- Figure 38: Asia Pacific Prostate Cancer Therapeutics Market Value (USD billion), by Disease State, 2025 & 2034
- Figure 39: Asia Pacific Prostate Cancer Therapeutics Market Value Share (%), by Disease State, 2025
- Figure 40: Asia Pacific Prostate Cancer Therapeutics Market Value (USD billion), by Distribution Channel, 2025 & 2034
- Figure 41: Asia Pacific Prostate Cancer Therapeutics Market Value Share (%), by Distribution Channel, 2025
- Figure 42: Asia Pacific Prostate Cancer Therapeutics Market Value (USD billion), By Country/ Sub-region, 2025 & 2034
- Figure 43: Asia Pacific Prostate Cancer Therapeutics Market Value Share (%), By Country/ Sub-region, 2025
- Figure 44: Latin America Prostate Cancer Therapeutics Market Value (USD billion), by Drug Class, 2025 & 2034
- Figure 45: Latin America Prostate Cancer Therapeutics Market Value Share (%), by Drug Class, 2025
- Figure 46: Latin America Prostate Cancer Therapeutics Market Value (USD billion), by Route of Administration, 2025 & 2034
- Figure 47: Latin America Prostate Cancer Therapeutics Market Value Share (%), by Route of Administration, 2025
- Figure 48: Latin America Prostate Cancer Therapeutics Market Value (USD billion), by Therapy, 2025 & 2034
- Figure 49: Latin America Prostate Cancer Therapeutics Market Value Share (%), by Therapy, 2025
- Figure 50: Latin America Prostate Cancer Therapeutics Market Value (USD billion), by Disease State, 2025 & 2034
- Figure 51: Latin America Prostate Cancer Therapeutics Market Value Share (%), by Disease State, 2025
- Figure 52: Latin America Prostate Cancer Therapeutics Market Value (USD billion), by Distribution Channel, 2025 & 2034
- Figure 53: Latin America Prostate Cancer Therapeutics Market Value Share (%), by Distribution Channel, 2025
- Figure 54: Latin America Prostate Cancer Therapeutics Market Value (USD billion), By Country/ Sub-region, 2025 & 2034
- Figure 55: Latin America Prostate Cancer Therapeutics Market Value Share (%), By Country/ Sub-region, 2025
- Figure 56: Middle East & Africa Prostate Cancer Therapeutics Market Value (USD billion), by Drug Class, 2025 & 2034
- Figure 57: Middle East & Africa Prostate Cancer Therapeutics Market Value Share (%), by Drug Class, 2025
- Figure 58: Middle East & Africa Prostate Cancer Therapeutics Market Value (USD billion), by Route of Administration, 2025 & 2034
- Figure 59: Middle East & Africa Prostate Cancer Therapeutics Market Value Share (%), by Route of Administration, 2025
- Figure 60: Middle East & Africa Prostate Cancer Therapeutics Market Value (USD billion), by Therapy, 2025 & 2034
- Figure 61: Middle East & Africa Prostate Cancer Therapeutics Market Value Share (%), by Therapy, 2025
- Figure 62: Middle East & Africa Prostate Cancer Therapeutics Market Value (USD billion), by Disease State, 2025 & 2034
- Figure 63: Middle East & Africa Prostate Cancer Therapeutics Market Value Share (%), by Disease State, 2025
- Figure 64: Middle East & Africa Prostate Cancer Therapeutics Market Value (USD billion), by Distribution Channel, 2025 & 2034
- Figure 65: Middle East & Africa Prostate Cancer Therapeutics Market Value Share (%), by Distribution Channel, 2025
- Figure 66: Middle East & Africa Prostate Cancer Therapeutics Market Value (USD billion), By Country/ Sub-region, 2025 & 2034
- Figure 67: Middle East & Africa Prostate Cancer Therapeutics Market Value Share (%), By Country/ Sub-region, 2025
- Figure 68: Global Prostate Cancer Therapeutics Market Share (%), By Company, 2025
